Comparative Pharmacology
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER versus RANICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER versus RANICLOR.
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER vs RANICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
None Documented
None Documented
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist